$176.30 Million in Sales Expected for Lannett Company, Inc. (LCI) This Quarter

Equities analysts expect Lannett Company, Inc. (NYSE:LCI) to report sales of $176.30 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Lannett’s earnings, with the highest sales estimate coming in at $182.14 million and the lowest estimate coming in at $172.60 million. Lannett reported sales of $165.72 million in the same quarter last year, which would indicate a positive year over year growth rate of 6.4%. The company is expected to report its next earnings results on Tuesday, May 1st.

On average, analysts expect that Lannett will report full year sales of $176.30 million for the current fiscal year, with estimates ranging from $681.80 million to $714.17 million. For the next fiscal year, analysts forecast that the company will post sales of $686.96 million per share, with estimates ranging from $653.68 million to $742.74 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Lannett.

How to Become a New Pot Stock Millionaire

Lannett (NYSE:LCI) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.20. The company had revenue of $184.31 million during the quarter, compared to analyst estimates of $190.92 million. Lannett had a net margin of 7.44% and a return on equity of 18.85%. Lannett’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.92 EPS.

LCI has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Lannett from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research note on Monday, December 11th. ValuEngine upgraded shares of Lannett from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Goldman Sachs initiated coverage on shares of Lannett in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $21.00 price objective for the company. BMO Capital Markets lowered their price objective on shares of Lannett from $22.00 to $21.00 and set a “market perform” rating for the company in a research note on Thursday, February 8th. Finally, Oppenheimer reiterated a “hold” rating on shares of Lannett in a research note on Monday, December 11th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.83.

In related news, major shareholder David Farber sold 10,000 shares of Lannett stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $25.01, for a total value of $250,100.00. Following the completion of the sale, the insider now owns 4,171,269 shares of the company’s stock, valued at approximately $104,323,437.69. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 14.72% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. LSV Asset Management grew its position in Lannett by 2.2% in the 4th quarter. LSV Asset Management now owns 1,835,535 shares of the company’s stock valued at $42,584,000 after purchasing an additional 40,000 shares during the period. Thompson Siegel & Walmsley LLC grew its position in Lannett by 20.5% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 1,010,232 shares of the company’s stock valued at $18,639,000 after purchasing an additional 171,751 shares during the period. Frontier Capital Management Co. LLC acquired a new stake in Lannett in the 4th quarter valued at $21,367,000. Russell Investments Group Ltd. grew its position in Lannett by 27.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 669,298 shares of the company’s stock valued at $12,349,000 after purchasing an additional 142,278 shares during the period. Finally, Deutsche Bank AG grew its position in Lannett by 3.7% in the 4th quarter. Deutsche Bank AG now owns 415,219 shares of the company’s stock valued at $9,631,000 after purchasing an additional 14,992 shares during the period. 98.40% of the stock is owned by institutional investors and hedge funds.

Lannett stock traded down $0.85 during trading hours on Thursday, hitting $15.65. 1,299,485 shares of the stock traded hands, compared to its average volume of 690,393. The company has a market cap of $592.26, a price-to-earnings ratio of 12.32, a P/E/G ratio of 1.00 and a beta of 2.63. The company has a quick ratio of 1.77, a current ratio of 2.32 and a debt-to-equity ratio of 1.38. Lannett has a 12 month low of $14.90 and a 12 month high of $30.35.

TRADEMARK VIOLATION WARNING: This story was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3300380/176-30-million-in-sales-expected-for-lannett-company-inc-lci-this-quarter.html.

Lannett Company Profile

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Get a free copy of the Zacks research report on Lannett (LCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lannett (NYSE:LCI)

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Q1 2018 EPS Estimates for Weatherford International  Decreased by Analyst
Q1 2018 EPS Estimates for Weatherford International Decreased by Analyst
Zymeworks  Expected to Post Q1 2018 Earnings of  Per Share
Zymeworks Expected to Post Q1 2018 Earnings of Per Share
PNM Resources  Plans Quarterly Dividend of $0.27
PNM Resources Plans Quarterly Dividend of $0.27
Fortune Brands Home & Security  Reaches New 12-Month High and Low at $55.55
Fortune Brands Home & Security Reaches New 12-Month High and Low at $55.55
Camping World  Sets New 12-Month High and Low at $25.91
Camping World Sets New 12-Month High and Low at $25.91
Panther Securities  Releases Quarterly  Earnings Results
Panther Securities Releases Quarterly Earnings Results


© 2006-2018 Ticker Report. Google+.